Provayblue (Methylene Blue) Patent Expiration, LOE Window & CMS Spending
Provayblue (Methylene Blue) by Provepharm Sas: FDA Orange Book LOE 2027-01-08, 0 AB generics, $725K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Provepharm Sas |
| FDA Application & Pathway | N204630 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-01-08 |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $725K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $725K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |